Morning Trend | DUALITYBIO's funds shrink again, is there a chance for a sector reversal on the way?

On December 29th, DUALITYBIO-B was under pressure throughout the day, with funds continuously observing around the range of 10.3-10.5 yuan. The biopharmaceutical sector as a whole is experiencing a volume contraction and consolidation, lacking significant positive news for the industry, leading investors to mainly adopt a wait-and-see approach in the short term. The MACD short-term moving average death cross signal persists, making it difficult to change the weak technical pattern for now. Leading pharmaceutical companies have not launched new drugs or secured cooperation orders, resulting in decreased market interest in short-term rotation speculation. Large funds are more focused on policy and industry conference developments. If there is a breakout with increased volume during the trading session, it may attract short-term speculative funds; otherwise, the weak oscillation situation will continue, and risks need to be continuously monitored